Aaron Gerds, MD, Cleveland Clinic, Cleveland, OH, outlines unmet needs in the fields of essential thrombocythemia and polycythemia vera by highlighting limitations of current treatments and the prospects of novel therapies. Dr Gerds specifically discusses the issue of symptom burden which the current treatment options phlebotomy, hydroxyurea, and anagrelide fail to address. Dr Gerds further talks on the need for more disease-modifying treatments which can reduce allele burden, target the disease on a clonal level, and delay progression. This interview took place at the Texas MPN Workshop: Second Annual Workshop and Meeting in 2021.

свернуть